Kymera Investor Presentation Deck

TARGET SELECTION Kymera: A Differentiated Approach to TPD Undrugged (UD) or inadequately drugged (ID) targets UD Transcription Factors (e.g. STAT3) KYMERA ID Degrader Advantage Over SMI (e.g. IRAK4, MDM2) Strong genetic validation within clinically validated pathway ©2023 KYMERA THERAPEUTICS, INC. PLATFORM Significantly differentiated investments Tissue- selective E3 Ligases Enabling a whole new generation of clinical programs New Molecular Glue Approach Novel strategy to address undrugged/ unligandable targets CLINICAL TRANSLATION Fidelity of translation of PK, PD and safety in 4 programs in immunology and oncology 0 Percent Change from Baseline IRAK4 -20 -40 -60 -80 % Change from C1D1 Predose (Mean ± SEM) -100 -20 0 4 8 12 16 20 24 28 32 36 40 -40 -60 -80- -100 KT-333 1 MAD PART C Cycle 1 weeks 1 & 2 T T T T 2 3 4 5 6 7 8 9 10 11 12 Days in Study PAGE 5

View entire presentation